Ultragenyx (RARE) outlook: rare-disease pipeline with 2026–2027 catalysts (GTX-102, DTX401, UX111) and $1.5B–$2.4B peak sales ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results